Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Castle Biosciences, Inc. (CSTL : NSDQ)

• Company Description    Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States. Number of Employees: 761

• Price / Volume Information    Yesterday's Closing Price: $38.90 Daily Weekly Monthly 20 Day Moving Average: 329,741 shares Shares Outstanding: 29.19 (millions) Market Capitalization: $1,135.44 (millions) Beta: 1.06 52 Week High: $42.18 52 Week Low: $14.59 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.82% -1.65% 12 Week 64.41% 61.76% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 505 S. Friendswood Drive Suite 401 - Friendswood,TX 77546 USA ph: 866-788-9007 fax: - ir@castlebiosciences.com https://castlebiosciences.com

• General Corporate Information    Officers Derek J. Maetzold - President and Chief Executive Officer Daniel M. Bradbury - Chairperson of the Board of Directors Frank Stokes - Chief Financial Officer Kimberlee S. Caple - Director G. Bradley Cole - Director Peer Information Castle Biosciences, Inc. (CORR.) Castle Biosciences, Inc. (RSPI) Castle Biosciences, Inc. (CGXP) Castle Biosciences, Inc. (BGEN) Castle Biosciences, Inc. (GTBP) Castle Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 14843C105 SIC: 8071 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 29.19 Most Recent Split Date: (:1) Beta: 1.06 Market Capitalization: $1,135.44 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.34 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.05 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 155.60 PEG Ratio: - Price Ratios Price/Book: 2.43 Price/Cash Flow: 39.54 Price / Sales: 3.31 EPS Growth vs. Year Ago Period: -125.00% vs. Previous Quarter: -113.33% Sales Growth vs. Year Ago Period: -3.19% vs. Previous Quarter: -3.65% ROE 12/31/25 - - 09/30/25 - 1.73 06/30/25 - 2.37 ROA 12/31/25 - - 09/30/25 - 1.47 06/30/25 - 2.03 Current Ratio 12/31/25 - - 09/30/25 - 6.47 06/30/25 - 6.85 Quick Ratio 12/31/25 - - 09/30/25 - 6.31 06/30/25 - 6.69 Operating Margin 12/31/25 - - 09/30/25 - 2.29 06/30/25 - 3.07 Net Margin 12/31/25 - - 09/30/25 - -3.56 06/30/25 - -2.73 Pre-Tax Margin 12/31/25 - - 09/30/25 - -5.51 06/30/25 - -2.96 Book Value 12/31/25 - - 09/30/25 - 16.00 06/30/25 - 15.70 Inventory Turnover 12/31/25 - - 09/30/25 - 8.61 06/30/25 - 8.80 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.02 06/30/25 - 0.02 Debt-to-Capital 12/31/25 - - 09/30/25 - 2.18 06/30/25 - 1.82

Powered by Zacks Investment Research ©